GlassScriptPhysician profile
Vicki M Hansen
NPI 1124560206
$3,186.47
in general payments reported to CMS, 2019-2025
28 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.07 · 2022: $624 · 2023: $584 · 2024: $761 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $518.84 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $385.70 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $343.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $312.18 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $251.71 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $203.85 | 2022-2025 | |
| Shockwave Medical, INC | $172.77 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.56 | 2022-2025 | Jardiance, Glyxambi, Trijardy Xr |
| Novartis Pharmaceuticals Corporation | $137.73 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $93.70 | 2022 | |
| Harmony Biosciences LLC | $76.12 | 2023-2025 | Wakix |
| Kowa Pharmaceuticals America, INC. | $71.50 | 2022-2025 | Zoryve |
| Exact Sciences Corporation | $51.57 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $46.82 | 2021-2022 | |
| Mylan Specialty L.P. | $46.04 | 2022-2023 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.60 | 2021-2022 | |
| Glaxosmithkline, LLC. | $41.77 | 2023-2025 | Shingrix, Bexsero, Pediarix |
| Sanofi Pasteur INC. | $35.37 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $33.36 | 2023 | Rexulti |
| Viatris Specialty LLC | $32.97 | 2025 | Yupelri |
| Lexicon Pharmaceuticals, INC. | $31.32 | 2024 | |
| Astellas Pharma US INC | $22.12 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $21.65 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $16.48 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $13.83 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $12.30 | 2022 | |
| Eisai INC. | $11.84 | 2021 | |
| Genentech USA, INC. | $5.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.